alutard sq bigift 100 000 sq-e/ml injektionsvätska, suspension
alk-abelló a/s - allergen, bigift - injektionsvätska, suspension - 100 000 sq-e/ml - allergen, bigift 100000 sq-u aktiv substans; aluminiumoxid, hydratiserad 4 mg adjuvans - insekter
alutard sq bigift styrkeserie injektionsvätska, suspension
alk-abelló a/s - allergen, bigift - injektionsvätska, suspension - styrkeserie - allergen, bigift 1000 sq-u aktiv substans; aluminiumoxid, hydratiserad 4 mikrog adjuvans; allergen, bigift 100 sq-u aktiv substans; aluminiumoxid, hydratiserad 0,04 mg adjuvans; aluminiumoxid, hydratiserad 4 mg adjuvans; allergen, bigift 10000 sq-u aktiv substans; aluminiumoxid, hydratiserad 0,4 mg adjuvans; allergen, bigift 100000 sq-u aktiv substans - insekter
alutard sq getinggift 100 000 sq-e/ml injektionsvätska, suspension
alk-abelló a/s - allergen, getinggift - injektionsvätska, suspension - 100 000 sq-e/ml - aluminiumoxid, hydratiserad 4 mg adjuvans; allergen, getinggift 100000 sq-u aktiv substans - insekter
alutard sq getinggift styrkeserie injektionsvätska, suspension
alk-abelló a/s - allergen, getinggift - injektionsvätska, suspension - styrkeserie - allergen, getinggift 100000 sq-u aktiv substans; aluminiumoxid, hydratiserad 4 mg adjuvans; aluminiumoxid, hydratiserad 0,4 mg adjuvans; allergen, getinggift 10000 sq-u aktiv substans; aluminiumoxid, hydratiserad 0,04 mg adjuvans; allergen, getinggift 1000 sq-u aktiv substans; aluminiumoxid, hydratiserad 4 mikrog adjuvans; allergen, getinggift 100 sq-u aktiv substans - insekter
xoterna breezhaler
novartis europharm limited - indakaterol, glycopyrronium bromid - pulmonell sjukdom, kronisk obstruktiv - adrenergika i kombination med antikolinergika inkl. trippel kombinationer med kortikosteroider - xoterna breezhaler är indicerat som underhållsbronkodilatorbehandling för att lindra symtom hos vuxna patienter med kronisk obstruktiv lungsjukdom (copd).
ultibro breezhaler
novartis europharm limited - indakaterol, glycopyrronium bromid - pulmonell sjukdom, kronisk obstruktiv - adrenergika i kombination med antikolinergika inkl. trippel kombinationer med kortikosteroider, läkemedel mot obstruktiv lungsjukdom, - ultibro breezhaler är indicerat som underhållsbronkodilatorbehandling för att lindra symtom hos vuxna patienter med kronisk obstruktiv lungsjukdom (kol).
budesonide/formoterol teva pharma b.v.
teva pharma b.v. - budesonide, formoterol - astma - läkemedel mot obstruktiv lungsjukdom, - budesonid / formoterol teva pharma b. indikeras endast hos vuxna 18 år och äldre. asthmabudesonide/formoterol teva pharma b. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists. in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.
ulunar breezhaler
novartis europharm limited - glycopyrronium bromid, indakaterol maleate - pulmonell sjukdom, kronisk obstruktiv - läkemedel mot obstruktiv lungsjukdom, - ulunar breezhaler indikeras som en underhållsbronkodilatorbehandling för att lindra symtom hos vuxna patienter med kronisk obstruktiv lungsjukdom (kol).
abiraterone accord
accord healthcare s.l.u. - abirateronacetat - prostatiska neoplasmer - endokrin terapi - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
abiraterone mylan
mylan ireland limited - abirateronacetat - prostatiska neoplasmer - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.